INS and fatty liver disease: To determine whether the reductions in hepatic steatosis that were observed with GC-1 and KB2115 treatment coincided with improvements in insulin sensitivity, we measured fasting glucose and insulin levels and determined insulin sensitivity using the homeostasis model assessment of insulin resistance (HOMA-IR) on mice treated with either GC-1 or KB2115.